Upon the announcement of Agnafit Bidco's SEK 235 per share bid for Sobi on September 2, 2021, Investor AB, in line with the recommendation by Sobi's Board of Directors, declared its support for the bid. As announced earlier today, Agnafit Bidco has decided to withdraw its bid for Sobi, following insufficient acceptance of the bid.
"We were instrumental in the creation of Sobi more than ten years ago. Under our ownership Sobi has built a leading hemophilia franchise greatly benefitting patients and broadened its product portfolio within Hematology and Immunology, organically and through major acquisitions. Our focus is now to continue to create long-term value for Sobi's shareholders" says Investor's President and CEO Johan Forssell.
Investor AB owns 35.0 percent of the capital and votes in Sobi.
For further information:
Viveka Hirdman-Ryrberg, Head of Corporate Communication and Sustainability,
Phone +46 70 550 3500
Magnus Dalhammar, Head of Investor Relations,
Phone +46 73 524 2130
Our press releases can be accessed at www.investorab.com
Investor, founded by the Wallenberg family in 1916, is an engaged owner of high quality global companies. We have a long-term investment perspective. Through board participation, as well as industrial experience, our network and financial strength, we work continuously to support our companies to remain or become best-in-class. Our holdings include, among others, ABB, Atlas Copco, Ericsson, Mölnlycke and SEB.
(c) 2021 Cision. All rights reserved., source Press Releases - English